Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): Efficacy in patients with visceral metastases

被引：8
|
作者：
Tung, Nadine M.
Im, Seock-Ah
Senkus-Konefka, Elzbieta
Xu, Binghe
Domchek, Susan M.
Masuda, Norikazu
Li, Wei
Armstrong, Anne Caroline
Conte, Pier Franco
Wu, Wenting
Goessl, Carsten Dietrich
Runswick, Sarah
Robson, Mark E.
机构：
[1] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[2] Dana Farber Harvard Canc Ctr, Boston, MA USA
[3] Seoul Natl Univ Hosp, Canc Res Inst, Seoul, South Korea
[4] Med Univ Gdansk, Gdansk, Poland
[5] Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, Dept Med Oncol, Beijing, Peoples R China
[6] Peking Union Med Coll CAMS & PUMC, Beijing, Peoples R China
[7] Univ Penn, Basser Ctr, Philadelphia, PA 19104 USA
[8] Natl Hosp Org, Osaka, Japan
[9] Jilin Univ, Hosp 1, Changchun, Peoples R China
[10] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England
[11] Univ Padua, Padua, Italy
[12] Ist Oncol Veneto IRCCS, Padua, Italy
[13] AstraZeneca, Gaithersburg, MD USA
[14] AstraZeneca, Macclesfield, Cheshire, England
[15] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.1052
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1052
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutation.
    Sun, Tao
    Shi, Yanxia
    Cui, Jiuwei
    Yin, Yongmei
    Ouyang, Quchang
    Liu, Qiang
    Zhang, Qingyuan
    Chen, Yiding
    Shao Zhimin
    Wang, Shouman
    Wang, Xiaojia
    Tong, Zhongsheng
    Zhong, Yahua
    Yan, Min
    Yan, Xi
    Wang, Chuan
    Yang, Haiyuan
    Li, Miao
    Xiang, Xiao
    Xu, Binghe
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [22] LUCY: A phase IIIb, real-world study of olaparib in HER2-negative metastatic breast cancer patients with a BRCA mutation
    Gelmon, K. A.
    Walker, G. P.
    Fisher, G. V.
    McCutcheon, S. C.
    ANNALS OF ONCOLOGY, 2018, 29
  • [23] Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies
    Morganti, Stefania
    Bychkovsky, Brittany L.
    Poorvu, Philip D.
    Garrido-Castro, Ana C.
    Weiss, Anna
    Block, Caroline C.
    Partridge, Ann H.
    Curigliano, Giuseppe
    Tung, Nadine M.
    Lin, Nancy U.
    Garber, Judy E.
    Tolaney, Sara M.
    Lynce, Filipa
    ONCOLOGIST, 2023, 28 (07): : 565 - 574
  • [24] Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation
    Schwartzberg, Lee S.
    Kiedrowski, Lesli A.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [25] Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer
    Morganti, Stefania
    Jin, Qingchun
    Vincuilla, Julie
    Buehler, Ryan
    Ryan, Sean
    Stokes, Samantha
    Parker, Tonia
    Mittendorf, Elizabeth A.
    King, Tari A.
    Weiss, Anna
    Partridge, Ann H.
    Bychkovsky, Brittany L.
    Curigliano, Giuseppe
    Tayob, Nabihah
    Lin, Nancy U.
    Garber, Judy E.
    Tolaney, Sara M.
    Lynce, Filipa
    NPJ BREAST CANCER, 2024, 10 (01)
  • [26] LUCY: A phase IIIb, single-arm, open-label multicenter study of olaparib in patients with HER2-negative metastatic breast cancer and a germline BRCA1/2 mutation
    Gelmon, Karen
    Walker, Graham P.
    Fisher, Graham V.
    CANCER RESEARCH, 2018, 78 (04)
  • [27] Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study
    Xu, Binghe
    Sun, Tao
    Shi, Yanxia
    Cui, Jiuwei
    Yin, Yongmei
    Ouyang, Quchang
    Liu, Qiang
    Zhang, Qingyuan
    Chen, Yiding
    Wang, Shouman
    Wang, Xiaojia
    Tong, Zhongsheng
    Zhong, Yahua
    Wang, Jiayu
    Yan, Min
    Yan, Xi
    Wang, Chuan
    Feng, Jifeng
    Wang, Xiuli
    Hu, Gang
    Cheng, Ying
    Ge, Ruimin
    Zhu, Zhaoyin
    Zhang, Wa
    Shao, Zhimin
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 197 (3) : 489 - 501
  • [28] Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation
    Frenel, J. -S.
    Lusque, A.
    Delaloge, S.
    Ferrero, J. -M.
    Bachelot, T.
    Desmoulins, I.
    Levy, C.
    Eymard, J. -C.
    Goncalves, A.
    Patsouris, A.
    Reynier, M. A. Mouret
    Thery, M. J. -C.
    Petit, T.
    Cabel, L.
    Uwer, L.
    Debled, M.
    Chevrot, M.
    Mailliez, A.
    Jacot, W.
    Rouge, T. de la Motte
    BRITISH JOURNAL OF CANCER, 2023, 128 (11) : 2072 - 2080
  • [29] Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation
    J.-S. Frenel
    A. Lusque
    S. Delaloge
    J.-M. Ferrero
    T. Bachelot
    I. Desmoulins
    C. Levy
    J.-C. Eymard
    A. Gonçalves
    A. Patsouris
    M. A. Mouret Reynier
    M. J.-C. Thery
    T. Petit
    L. Cabel
    L. Uwer
    M. Debled
    M. Chevrot
    A. Mailliez
    W. Jacot
    T. de La Motte Rouge
    British Journal of Cancer, 2023, 128 : 2072 - 2080
  • [30] Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study
    Binghe Xu
    Tao Sun
    Yanxia Shi
    Jiuwei Cui
    Yongmei Yin
    Quchang Ouyang
    Qiang Liu
    Qingyuan Zhang
    Yiding Chen
    Shouman Wang
    Xiaojia Wang
    Zhongsheng Tong
    Yahua Zhong
    Jiayu Wang
    Min Yan
    Xi Yan
    Chuan Wang
    Jifeng Feng
    Xiuli Wang
    Gang Hu
    Ying Cheng
    Ruimin Ge
    Zhaoyin Zhu
    Wa Zhang
    Zhimin Shao
    Breast Cancer Research and Treatment, 2023, 197 : 489 - 501
12345